11. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. (October 2020) Authors: Schrezenmeier, Hubert; Kulasekararaj, Austin; Mitchell, Lindsay; Sicre de Fontbrune, Flore; Devos, Timothy; Okamoto, Shinichiro; Wells, Richard; Rottinghaus, Scott T.; Liu, Peng; Ortiz, Stephan; Lee, Jong Wook; Socié, Gérard Journal: Therapeutic advances in hematology Issue: Volume 11(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. (June 2018) Authors: Mora, Barbara; Giorgino, Toni; Guglielmelli, Paola; Rumi, Elisa; Maffioli, Margherita; Rambaldi, Alessandro; Caramella, Marianna; Komrokji, Rami; Gotlib, Jason; Kiladjian, Jean Jacques; Cervantes, Francisco; Devos, Timothy; Palandri, Francesca; De Stefano, Valerio; Ruggeri, Marco; Silver, Richard... Journal: Leukemia research Issue: Volume 69(2018) Page Start: 100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Recanalization of portal axis after cavoportal hemitransposition in a liver transplant recipient with complete splanchnic thrombosis. (21st July 2021) Authors: Clarysse, Mathias; Wilmer, Alexander; Debaveye, Yves; Laleman, Wim; Devos, Timothy; Canovai, Emilio; Verslype, Chris; van der Merwe, Schalk; van Malenstein, Hannah; Nevens, Frederik; Maleux, Geert; Sainz‐Barriga, Mauricio; Monbaliu, Diethard; Pirenne, Jacques Journal: Pediatric transplantation Issue: Volume 25:Number 8(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Issue 4 (21st April 2018) Authors: Devos, Timothy; Selleslag, Dominik; Zachée, Pierre; Benghiat, Fleur Samantha Journal: Hematology Issue: Volume 23:Issue 4(2018) Page Start: 194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Issue 1 (January 2017) Authors: Passamonti, Francesco; Griesshammer, Martin; Palandri, Francesca; Egyed, Miklos; Benevolo, Giulia; Devos, Timothy; Callum, Jeannie; Vannucchi, Alessandro M; Sivgin, Serdar; Bensasson, Caroline; Khan, Mahmudul; Mounedji, Nadjat; Saydam, Guray Journal: Lancet oncology Issue: Volume 18:Issue 1(2017:Jan.) Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Issue 7 (July 2022) Authors: Passamonti, Francesco; Palandri, Francesca; Saydam, Guray; Callum, Jeannie; Devos, Timothy; Guglielmelli, Paola; Vannucchi, Alessandro M; Zor, Evren; Zuurman, Mike; Gilotti, Geralyn; Zhang, Yifan; Griesshammer, Martin Journal: Lancet Issue: Volume 9:Issue 7(2022) Page Start: e480 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Issue 14 (6th December 2019) Authors: Foltz, Lynda; Pica, Gian-Matteo; Zerazhi, Hacene; Van Droogenbroeck, Jan; Visanica, Sorin; Báez de la Fuente, Enrique; Leber, Brian; de Almeida, Antonio Medina; Ranta, Dana; Kiladjian, Jean-Jacques; Chrit, Linda; Kandra, Albert; Morando, Juliane; Devos, Timothy Journal: Leukemia & lymphoma Issue: Volume 60:Issue 14(2019) Page Start: 3493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1. (26th February 2014) Authors: AL Assaf, Carla; Lierman, Els; Devos, Timothy; Billiet, Johan; Graux, Carlos; Papadopoulos, Petros; Vandenberghe, Peter Journal: British journal of haematology Issue: Volume 165:Number 5(2014:Jun.) Page Start: 734 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review. Issue 12 (December 2022) Authors: Houthuys, Jona F.; Wilmer, Alexander P.; Peetermans, Marijke; Meersseman, Philippe; Devos, Timothy Journal: Heliyon Issue: Volume 8:Issue 12(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Issue 1 (1st January 2022) Authors: Devos, Timothy; Selleslag, Dominik; Granacher, Nikki; Havelange, Violaine; Benghiat, Fleur Samantha Journal: Hematology Issue: Volume 27:Issue 1(2022) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗